| fluoxetine / Generic mfg. |
NCT00018174: Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers |
|
|
| Completed | 3 | 247 | US | Fluoxetine, Behavioral group smoking cessation treatment, Placebo | US Department of Veterans Affairs, Eli Lilly and Company | Depression, Smoking | 01/03 | 01/05 | | |
2004-004008-19: Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel groups, international study versus fluoxetine (20 mg/day with potential adjustment to 40 mg) with a double-blind extension period of 16 weeks. |
|
|
| Completed | 3 | 500 | Europe | S20098, Fluoxetine, S20098, Capsule, hard, PROZAC | Institut de Recherches Internationales Servier, Laboratorios Servier S.L. (For Spain only), SERVIER Research and Development ICTR (For United Kingdom only), INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | Severe Major Depressive Disorder | | | | |
| Completed | 3 | 494 | Canada, Europe, RoW | Quetiapine, Amitriptyline, Bupropion, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine | AstraZeneca | Major Depressive Disorder | | 04/07 | | |
| Completed | 3 | 158 | US | Fluoxetine, NPL-2008, Placebo | Neuropharm, Autism Speaks | Autistic Disorder | 01/09 | 01/09 | | |
| Terminated | 3 | 128 | US | Fluoxetine (prozac) | Neuropharm, Autism Speaks | Autistic Disorder | 04/09 | 04/09 | | |
| Completed | 3 | 463 | US, Canada, RoW | Placebo, fluoxetine, LY110140, Prozac, duloxetine, LY248686, Cymbalta | Eli Lilly and Company | Major Depressive Disorder | 02/11 | 09/11 | | |
| Completed | 3 | 337 | US, Europe, RoW | duloxetine, LY248686, Cymbalta, Placebo, fluoxetine, LY110140, Prozac | Eli Lilly and Company | Major Depressive Disorder | 03/11 | 10/11 | | |
NCT01808612: A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing |
|
|
| Completed | 3 | 513 | Japan | Fluoxetine, LY110140, Fluoxetine Hydrochloride, Prozac, Sarafem, Placebo | Eli Lilly and Company | Major Depressive Disorder | 07/14 | 07/14 | | |
| Completed | 3 | 200 | Japan | Fluoxetine, LY110140, Fluoxetine Hydrochloride, Prozac, Sarafem | Eli Lilly and Company | Major Depressive Disorder | 03/15 | 03/15 | | |
| Completed | 3 | 340 | US, RoW | desvenlafaxine succinate sustained release, fluoxetine, placebo | Pfizer | Major Depressive Disorder | 03/15 | 03/15 | | |
NCT01687478: A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression |
|
|
| Terminated | 3 | 176 | RoW | Olanzapine, LY170053, Zyprexa, Fluoxetine, LY110140, Prozac, Placebo | Eli Lilly and Company | Treatment Resistant Depression | 11/15 | 11/15 | | |
2015-002181-23: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depressive Disorder. |
|
|
| Ongoing | 3 | 484 | Europe, RoW | Agomelatine, Fluoxetine, S20098, Film-coated tablet, Oral solution, Valdoxan, Fluoxetine | Institut de Recherche International Servier, ADIR | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 3 | 2944 | Canada, US, Europe, RoW | OPC-34712, Escitalopram, Lexapro, Fluoxetine, Prozac, Paroxetine CR, Paxil CR, Sertraline, Zoloft, Duloxetine, Cymbalta, Venlafaxine XR, Effexor XR | Otsuka Pharmaceutical Development & Commercialization, Inc. | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | 04/17 | 05/17 | | |
|
NCT03087916: Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder |
|
|
| Recruiting | 3 | 660 | US | Placebo, Levomilnacipran ER, Fetzima, Fluoxetine, Prozac | Allergan | Major Depressive Disorder (MDD) | 03/18 | 03/18 | | |
| Completed | 3 | 473 | Canada, US | Vilazodone, Viibryd, Placebo, Fluoxetine, Prozac | Forest Laboratories | Major Depressive Disorder | 09/18 | 09/18 | | |
NCT02709746 / 2008-005354-20: Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) |
|
|
| Completed | 3 | 784 | Europe, Canada, US, RoW | Vortioxetine 10 mg/day, Brintellix ®, Lu AA21004, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo | H. Lundbeck A/S, Takeda | Depressive Disorder, Major | 07/19 | 07/19 | | |
NCT02431806: Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder |
|
|
| Completed | 3 | 552 | US | Placebo, Levomilnacipran, Fetzima, Fluoxetine, Prozac | Forest Laboratories | Major Depressive Disorder | 08/19 | 08/19 | | |
NCT03569475: Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder |
|
|
| Completed | 3 | 501 | US | Levomilnacipran ER, Fluoxetine, Placebo | Allergan | Major Depressive Disorder | 03/21 | 03/21 | | |
NCT02709655 / 2008-005353-38: Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) |
|
|
| Completed | 3 | 683 | Europe, Canada, US, RoW | Vortioxetine 10 mg/day, Brintellix ®, Lu AA21004, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo | H. Lundbeck A/S, Takeda | Depressive Disorder, Major | 01/22 | 01/22 | | |
NCT03538691 / 2018-000601-22: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 1149 | US | Brexpiprazole, OPC-34712, Rexulti, Antidepressant therapy | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 07/22 | 07/22 | | |
NCT04727424: Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms |
|
|
| Recruiting | 3 | 7819 | RoW | Spirulin Platensis, Budesonide Powder, Fluvoxamine Maleate 100 MG [Luvox], Fluoxetine 20 MG, Budesonide powder, Placebo | Cardresearch, Cytel Inc., McMaster University, Fastgrants, Eiger BioPharmaceuticals, RainWater Foundation | Covid19, SARS-Associated Coronavirus | 06/24 | 07/24 | | |
